Company Filing History:
Years Active: 2025
Title: Innovator Spotlight: Nicolas Felix Pierre Boutard
Introduction: Nicolas Felix Pierre Boutard is a notable inventor based in Cracow, Poland. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of innovative compounds essential for therapeutic applications.
Latest Patents: Nicolas Boutard holds a patent for "Selective Inhibitors of NLRP3 Inflammasome." The patent disclosure relates to compounds of Formula (I) and their pharmaceutically acceptable salts, as well as pharmaceutical compositions, methods of use, and methods of preparation. The compounds described are instrumental in inhibiting the maturation of cytokines from the IL-1 family by targeting inflammasomes. This research has potential applications in treating disorders that involve inflammasome activity, including autoinflammatory and autoimmune diseases, as well as certain types of cancers.
Career Highlights: Nicolas is affiliated with Nodthera Limited, a company focused on developing innovative therapies targeting inflammatory diseases. His engagement in this organization showcases his dedication to advancing medical science and improving patient outcomes through novel therapeutic approaches.
Collaborations: Throughout his career, Nicolas has collaborated with prominent colleagues, including Mark G. Bock and David Harrison. These collaborations highlight the importance of teamwork in the advancement of scientific research and the development of groundbreaking therapies.
Conclusion: Nicolas Felix Pierre Boutard exemplifies the spirit of innovation within the pharmaceutical sector. With his single but impactful patent, he continues to contribute to the scientific community's understanding and management of complex diseases. His work at Nodthera Limited signals a promising future for the therapeutic applications of his research.